{"id":9795,"date":"2004-05-02T20:07:38","date_gmt":"2004-05-02T20:07:38","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=9795"},"modified":"2014-05-22T17:20:33","modified_gmt":"2014-05-22T17:20:33","slug":"pk-of-once-daily-lopinavirr-in-children","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/9795","title":{"rendered":"PK of once daily lopinavir\/r in children"},"content":{"rendered":"<p><strong>Polly Clayden, HIV i-Base<\/strong><\/p>\n<p><strong>A report from Glenda Verweel et al from University Medical Centre in Rotterdam evaluated the pharmacokinetics of children on a QD dosing schedule of lopinavir\/ritonavir.<\/strong><\/p>\n<p>A group of 14 children on stable antiretroviral therapy with HIV-1 RNA below 50 copies for at least six months were switched to receive LPV\/r 460\/115 mg\/m2 QD with zidovudine and lamivudine BID as part of the RONDO trial. The LPV\/r dose was given with food.<\/p>\n<p>Samples were taken at 0, 2, 4, 6, 8, 12, 18 and 24 hours post dose. The target range for Cmin was 1.0mg\/L. The children received a median dose of 400mg LPV (range 282-533mg). The median dose per m2 was 461 mg (448-883 mg). The investigators reported steady state AUC (0-24h), Cmax, Tmax and Cmin (24h) to be similar to LPV\/r dosed at 800\/200 mg QD in adults.<\/p>\n<p>Of the children, only 3\/14 had Cmin (24h) levels considered to be too low, leading to dose increase. At three months follow up, 12\/13 children for whom data were available had HIV-1 RNA &lt;50 copies\/mL and one child had 52 copies\/mL.<\/p>\n<h3>Comment<\/h3>\n<p><strong>Like pregnant women, these last two studies show that if ever there is a population for which TDM is strongly indicated it is children.<\/strong><\/p>\n<p>Reference:<\/p>\n<p>Verweel G, van der Lee M, de Groot R et al. Pharmacokinetics of once daily lopinavir\/ritonavir in HIV-infected children. Abstract 7.1<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Polly Clayden, HIV i-Base A report from Glenda Verweel et al from University Medical Centre in Rotterdam evaluated the pharmacokinetics of children on a QD dosing schedule of lopinavir\/ritonavir. A group of 14 children on stable antiretroviral therapy with HIV-1 &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,32,34],"tags":[141],"class_list":["post-9795","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-paediatric-care","category-pk-and-drug-interactions","tag-pk-workshop-2004"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/9795","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=9795"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/9795\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=9795"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=9795"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=9795"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}